JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 244 products of "JAK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
FM-479
CAS:FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.
Formula:C25H26N6O2Purity:98%Color and Shape:SolidMolecular weight:442.523QL-1200186
CAS:QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production followingFormula:C26H27N7O3Purity:98%Color and Shape:SolidMolecular weight:485.54JAK-IN-24
CAS:JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.Formula:C20H25N5O2Color and Shape:SolidMolecular weight:367.44JAK-IN-3
CAS:JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.Formula:C18H20N4O3Purity:98.04% - 98.19%Color and Shape:SolidMolecular weight:340.38Ref: TM-T11704
1mg126.00€2mg178.00€5mg304.00€10mg492.00€25mg982.00€50mg1,558.00€100mg2,538.00€200mg3,402.00€1mL*10mM (DMSO)334.00€JAK1/TYK2-IN-4
CAS:JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].Formula:C17H23N7OColor and Shape:SolidMolecular weight:341.41JAK3-IN-11
CAS:JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Formula:C23H23N5O2Color and Shape:SolidMolecular weight:401.46JAK1-IN-9
CAS:JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.Formula:C16H13IN6Color and Shape:SolidMolecular weight:416.22Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Formula:C24H25N7O2Color and Shape:SolidMolecular weight:443.50GDC-9918
CAS:GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.Formula:C20H18F2N6O5SColor and Shape:SolidMolecular weight:492.46YLIU-4-105-1
CAS:YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Formula:C32H34F3N7O2Color and Shape:SolidMolecular weight:605.65Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Color and Shape:SolidJAK2 JH2 binder-1
CAS:JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.Formula:C29H25N7O6SColor and Shape:SolidMolecular weight:599.62JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFormula:C22H17FN6O2SPurity:98%Color and Shape:SolidMolecular weight:448.47JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Formula:C23H22Cl2N4OColor and Shape:SolidMolecular weight:441.35Ten01
Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.Formula:C18H20F6N4OColor and Shape:SolidMolecular weight:422.37TYK2 ligand 2
CAS:TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.Formula:C24H20FN7O4Color and Shape:SolidMolecular weight:489.458iBFAR2
CAS:iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.
Formula:C19H15F3N2O2Color and Shape:SolidMolecular weight:360.33JAK2-IN-11
CAS:JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formula:C31H31F3N8O4Color and Shape:SolidMolecular weight:639.64Tyk2-IN-3
CAS:Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).Formula:C25H24N6O3S2Purity:98%Color and Shape:SolidMolecular weight:520.63JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormula:C17H20N6OPurity:98.81%Color and Shape:SolidMolecular weight:324.38(3S,4R)-Tofacitinib
CAS:(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37PF-06263276
CAS:PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).Formula:C31H31FN8O2Purity:98%Color and Shape:SolidMolecular weight:566.63AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Formula:C20H28FN7Purity:98%Color and Shape:SolidMolecular weight:385.48lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468CP-352664
CAS:CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Formula:C18H18N4Color and Shape:SolidMolecular weight:290.36Milpecitinib
CAS:Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Formula:C20H20N4O2SColor and Shape:SolidMolecular weight:380.463LNK01004
CAS:LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.Formula:C26H31N7O2Color and Shape:SolidMolecular weight:473.57JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Formula:C26H36FN5O2Color and Shape:SolidMolecular weight:469.59CEE321
CAS:CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.Formula:C18H16ClN5OColor and Shape:SolidMolecular weight:353.806Londamocitinib
CAS:Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.Formula:C28H31F2N7O4SPurity:98.64% - 99.56%Color and Shape:SolidMolecular weight:599.65Ref: TM-T11706
1mg170.00€5mg416.00€10mg567.00€25mg858.00€50mg1,108.00€100mg1,485.00€1mL*10mM (DMSO)537.00€Tyk2-IN-14
CAS:Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formula:C22H21N9O2Color and Shape:SolidMolecular weight:443.46Tyk2-IN-15
CAS:Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].
Formula:C21H25F2N7OColor and Shape:SolidMolecular weight:429.47Tyk2-IN-10
CAS:Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.Formula:C25H27N5O3Color and Shape:SolidMolecular weight:445.51Tyk2-IN-17
CAS:Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.42JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formula:C28H39N3O3Color and Shape:SolidMolecular weight:465.63(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37JAK2-IN-9
CAS:Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.
Formula:C20H24N6O2SPurity:98%Color and Shape:SolidMolecular weight:412.51JAK1-IN-10
CAS:JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
Formula:C15H17N7Purity:98%Color and Shape:SolidMolecular weight:295.34JAK-IN-27
CAS:JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM
Formula:C20H21F2N7OPurity:98%Color and Shape:SolidMolecular weight:413.42JAK-IN-34
CAS:JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,
Formula:C27H26N6OPurity:98%Color and Shape:SolidMolecular weight:450.53STAT3-IN-18
CAS:STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and
Formula:C18H24Cl2N2O6PtPurity:98%Color and Shape:SolidMolecular weight:630.38JAK1-IN-11
CAS:JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.
Formula:C26H36N6O4SPurity:98%Color and Shape:SolidMolecular weight:528.67DPP
CAS:DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating
Formula:C36H40Cl2N2O10PtPurity:98%Color and Shape:SolidMolecular weight:926.7
